Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 542 shares at $6.39 ($3K) on 2011-09-28, disclosed to the SEC on 2011-09-28.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.38 | 15 | $96 | 2.8% |
| 2 | $6.39 | 527 | $3K | 97.2% |
| Total | $6.39 avg | 542 | $3K | 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |